|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
5K23CA113775-03
|
$134,015
|
$67,008
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Improving the Efficacy of Dendritic Cell Vaccines
|
5P01CA084512-07
|
$985,145
|
$197,029
|
Banchereau, Jacques
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Heat shock proteins in cancer and signaling
|
5R01CA081244-10
|
$343,115
|
$102,935
|
SHERMAN, MICHAEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Effects of mTOR inhibitors on multiple myeloma tumors
|
5K01CA111623-04
|
$149,580
|
$149,580
|
Frost, Patrick
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Use of CCI-779 in multiple myeloma
|
1R21CA121464-01A2
|
$319,950
|
$319,950
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Sensitivity Multiple Myeloma Cells to mTOR Inhibitors
|
5R01CA111448-04
|
$188,765
|
$188,765
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Energy Balance, IGF Dysregulation and Multiple Myeloma
|
5K07CA115687-03
|
$140,130
|
$140,130
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Carle Cancer Center Community Clinical Oncology Program
|
2U10CA035195-25
|
$855,703
|
$8,557
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
|
Cedar Rapids Oncology Project
|
2U10CA052352-19
|
$575,627
|
$5,756
|
WIESENFELD, MARTIN
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
|
A Novel Antibody Therapeutic for Multiple Myeloma
|
2R44CA105840-02A2
|
$279,125
|
$279,125
|
CHINTALACHARUVU, KOTESWARA
|
CHIMERIC TECHNOLOGIES, INC.
|
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-22
|
$1,042,698
|
$10,427
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
|
PHASE IIB RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF AN NSAID FOR THE MODULATION OF
|
N01CN025140-004
|
|
$0
|
HUSSEIN, MOHAMAD
|
Cleveland Clinic Foundation
|
|
|
CCOP: Colorado Cancer Research Program
|
5U10CA067753-13
|
$873,364
|
$8,734
|
Pajon, Eduardo
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
|
EFFECTS OF THE CHORNOBYL ACCIDENT ON THYROID CANCER AND LEUKEMIA AND RELATED DISE
|
N01CP021178-009
|
$280,000
|
$28,000
|
Zablotska, Lydia
|
COLUMBIA UNIV:1106394
|
|
|
Determinants and risks of use and overuse of expensive oncology drugs
|
1R01CA134964-01
|
$259,686
|
$51,937
|
HERSHMAN, DAWN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Columbus Community Clinical Oncology Program
|
5U10CA035261-25
|
$874,908
|
$8,749
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
|
Targeted Therapy of B-cell Malignancies
|
5P01CA103985-04
|
$1,618,062
|
$161,806
|
GOLDENBERG, DAVID
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
|
SPORE in Myeloma
|
2P50CA100707-06
|
$2,300,000
|
$2,300,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Host-Tumor Cell Interactions in Myeloma:
|
3P01CA078378-10S1
|
$1,346,410
|
$1,346,410
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S1
|
$124,531
|
$2,491
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S2
|
|
$0
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S3
|
$49,998
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S4
|
$143,383
|
$2,868
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S5
|
|
$0
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-44
|
$11,641,774
|
$232,835
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Selective Inhibition of HDAC6 in Cancer Therapy
|
1K08CA128972-01A1
|
$139,240
|
$139,240
|
BRADNER, JAMES
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CXCR4 regulation of tumor progression in Multiple Myeloma
|
1R01CA125690-01A2
|
$320,576
|
$320,576
|
Ghobrial, Irene
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma
|
1R01CA133799-01A1
|
$352,995
|
$352,995
|
Ghobrial, Irene
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Differentiating Agents in Hematologic Malignancies
|
2R01CA042802-21A1
|
$333,828
|
$166,914
|
KUFE, DONALD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
1R01CA124929-01A2
|
$354,825
|
$354,825
|
MUNSHI, NIKHIL
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Cancer and Leukemia Group B
|
5U10CA032291-27
|
$348,584
|
$17,429
|
WINER, ERIC
|
DANA-FARBER CANCER INSTITUTE
|
|
|
MODIFICATIONS MATTER IN MCL1 TURNOVER AND CELL VIABILITY
|
5R01CA057359-16
|
$308,120
|
$154,060
|
Craig, Ruth
|
DARTMOUTH COLLEGE
|
|
|
Cancer Center Support Grant
|
3P30CA023108-30S1
|
$88,511
|
$2,655
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
|
Cancer Center Support Grant
|
5P30CA023108-30
|
$3,107,727
|
$93,232
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
|
Different active sites of the proteasome as drug targets in cancer
|
5R01CA124634-02
|
$273,429
|
$136,715
|
Kisselev, Alexei
|
DARTMOUTH COLLEGE
|
|
|
BCMA: Controlling the survival of differentiated B cells
|
5R01CA108896-05
|
$248,647
|
$248,647
|
NOELLE, RANDOLPH
|
DARTMOUTH COLLEGE
|
|
|
Central Illinois Community Clinical Oncology Program
|
5U10CA045807-23
|
$1,053,633
|
$10,536
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
|
Cancer and Leukemia Group B
|
5U10CA047577-21
|
$166,705
|
$8,335
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
|
Cancer and Leukemia Group B Statistical Center
|
5U10CA033601-29
|
$5,067,063
|
$253,353
|
GEORGE, STEPHEN
|
DUKE UNIVERSITY
|
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-25
|
$798,586
|
$7,986
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
|
EORTC DATA CENTER
|
5U10CA011488-38
|
$793,241
|
$7,932
|
Sylvester, Richard
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
|
Community Clinical Oncology Program
|
2U10CA035199-25
|
$484,645
|
$4,846
|
GRINBLATT, DAVID
|
EVANSTON NORTHWESTERN HEALTHCARE
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-34S4
|
$9,979,932
|
$99,799
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-34S5
|
$60,810
|
$608
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-34S6
|
$264,000
|
$2,640
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Mixed Hematopoietic Chimerism after Stem Cell Allografts
|
5P01CA078902-10
|
$2,003,834
|
$500,959
|
Storb, Rainer
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
ECOG CCOP Research Base
|
5U10CA037403-23
|
$1,797,715
|
$53,931
|
COMIS, ROBERT
|
FRONTIER SCI & TECHNOLOGY RSCH FDN, INC
|
|
|
ECOG Specimen Banking
|
5U24CA114737-04
|
$870,071
|
$435,036
|
COMIS, ROBERT
|
FRONTIER SCI & TECHNOLOGY RSCH FDN, INC
|
|
|
Cancer and Leukemia Group B
|
5U10CA077597-11
|
$121,638
|
$6,082
|
Liu, Minetta
|
GEORGETOWN UNIVERSITY
|
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-10S1
|
$125,023
|
$5,001
|
DALTON, WILLIAM
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Total relevant funding to Multiple Myeloma for this search: $41,541,846
|
